Table 3.
Clinical efficacy and safety outcomes
| Efficacy and safety | Results |
|---|---|
| 24-hour NIHSS, mean (IQR) | 13 (4–18) |
| Early neurological improvement, n (%)a | 28 (53.8) |
| NIHSS at discharge, mean (IQR) | 5 (1–11) |
| mRS at discharge, n (%) | |
| 0–1 | 8 (15.4) |
| 0–2 | 15 (28.8) |
| 3 | 8 (15.4) |
| 4 | 13 (25) |
| 5 | 7 (13.5) |
| 6 | 9 (17.3) |
| mRS at 90 days, n (%) | |
| 0–1 | 20 (38.5) |
| 0–2 | 24 (46.2) |
| 3 | 4 (7.7) |
| 4 | 6 (11.5) |
| 5 | 3 (5.8) |
| 6 | 15 (28.8) |
| Intracranial hemorrhage, n (%) | |
| sICH | 1 (1.9) |
| All ICH | 10 (19.2) |
| Early neurological deterioration, n (%) | 7 (13.5) |
| All-cause mortality at 90 days, n (%) | 15 (28.8) |
| In hospital mortality, n (%) | 9 (17.3) |
| Serious device-related adverse events, n (%) | 0 (0) |
| Serious procedure related adverse events, n (%)b | 1 (1.9) |
NIHSS National Institute of Health Stroke Scale score, IQR interquartile range, mRS modified Rankin Scale score, sICH symptomatic intracranial hemorrhage, ICH intracranial hemorrhage
a Early neurological improvement was defined as a reduction of ≥ 5 points on the NIHSS or an NIHSS score < 4 at 24-hours
b Microwire perforation with contrast extravasation on angiography